These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 11213526)

  • 1. Mechanism of cell death in experimental models of Parkinson's disease.
    Hirsch EC; Hunot S; Hartmann A
    Funct Neurol; 2000; 15(4):229-37. PubMed ID: 11213526
    [No Abstract]   [Full Text] [Related]  

  • 2. Apoptotic neuronal death in Parkinson's disease: involvement of nitric oxide.
    Singh S; Dikshit M
    Brain Res Rev; 2007 Jun; 54(2):233-50. PubMed ID: 17408564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The functional anatomy of noradrenergic neurons in Parkinson's disease.
    Soldani P; Fornai F
    Funct Neurol; 1999; 14(2):97-109. PubMed ID: 10399622
    [No Abstract]   [Full Text] [Related]  

  • 4. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroinflammatory processes in Parkinson's disease.
    Hunot S; Hirsch EC
    Ann Neurol; 2003; 53 Suppl 3():S49-58; discussion S58-60. PubMed ID: 12666098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
    Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
    Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mapping neuronal activity of the basal ganglia in experimental models of Parkinson's disease: contributions of the [14C]2-deoxyglucose method.
    Orzi F; Fornai F; Blandini F
    Funct Neurol; 2000; 15(4):269-76. PubMed ID: 11213530
    [No Abstract]   [Full Text] [Related]  

  • 8. Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons.
    Porritt MJ; Batchelor PE; Howells DW
    Exp Neurol; 2005 Mar; 192(1):226-34. PubMed ID: 15698637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.
    Huot P; Lévesque M; Parent A
    Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are dopaminergic neurons selectively vulnerable to Parkinson's disease?
    Agid Y; Ruberg M; Javoy-Agid F; Hirsch E; Raisman-Vozari R; Vyas S; Faucheux B; Michel P; Kastner A; Blanchard V
    Adv Neurol; 1993; 60():148-64. PubMed ID: 8420132
    [No Abstract]   [Full Text] [Related]  

  • 11. Dopamine cell degeneration induced by intraventricular administration of 6-hydroxydopamine in the rat: similarities with cell loss in parkinson's disease.
    Rodríguez M; Barroso-Chinea P; Abdala P; Obeso J; González-Hernández T
    Exp Neurol; 2001 May; 169(1):163-81. PubMed ID: 11312569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathophysiology of Parkinson's disease.
    Bonnet AM; Houeto JL
    Biomed Pharmacother; 1999 Apr; 53(3):117-21. PubMed ID: 10349507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MAPKAP kinase 2-deficiency prevents neurons from cell death by reducing neuroinflammation--relevance in a mouse model of Parkinson's disease.
    Thomas T; Timmer M; Cesnulevicius K; Hitti E; Kotlyarov A; Gaestel M
    J Neurochem; 2008 Jun; 105(5):2039-52. PubMed ID: 18298661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteopontin is elevated in Parkinson's disease and its absence leads to reduced neurodegeneration in the MPTP model.
    Maetzler W; Berg D; Schalamberidze N; Melms A; Schott K; Mueller JC; Liaw L; Gasser T; Nitsch C
    Neurobiol Dis; 2007 Mar; 25(3):473-82. PubMed ID: 17188882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroprotective effect of nicotine on dopaminergic neurons by anti-inflammatory action.
    Park HJ; Lee PH; Ahn YW; Choi YJ; Lee G; Lee DY; Chung ES; Jin BK
    Eur J Neurosci; 2007 Jul; 26(1):79-89. PubMed ID: 17581257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and kainic acid-induced up-regulation of low-affinity p75 neurotrophin receptor (p75NTR) in the nigral dopamine neurons of adult rats.
    Wang YQ; Bian GL; Bai Y; Cao R; Chen LW
    Neurochem Int; 2008 Sep; 53(3-4):56-62. PubMed ID: 18639597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Growth factors as neuroprotective treatment in Parkinson disease?].
    Torp R; Singh PB; Sørensen DR; Dietrichs E; Hirschberg H
    Tidsskr Nor Laegeforen; 2006 Mar; 126(7):899-901. PubMed ID: 16554879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hippocampal neuron and glial cell numbers in Parkinson's disease--a stereological study.
    Joelving FC; Billeskov R; Christensen JR; West M; Pakkenberg B
    Hippocampus; 2006; 16(10):826-33. PubMed ID: 16941622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined toxicity of prenatal bacterial endotoxin exposure and postnatal 6-hydroxydopamine in the adult rat midbrain.
    Ling ZD; Chang Q; Lipton JW; Tong CW; Landers TM; Carvey PM
    Neuroscience; 2004; 124(3):619-28. PubMed ID: 14980732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.
    Zheng JS; Tang LL; Zheng SS; Zhan RY; Zhou YQ; Goudreau J; Kaufman D; Chen AF
    Brain Res Mol Brain Res; 2005 Mar; 134(1):155-61. PubMed ID: 15790539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.